Spiliotis et al. randomized 120 patients with relapsed ovarian cancer to treatment with cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) before systemic chemotherapy.
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TO THE EDITORS
Spiliotis et al. randomized 120 patients with relapsed ovarian cancer to treatment with cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) before systemic chemotherapy. 1 They showed amazingly positive results favoring the HIPEC arm, with a mean survival double that reported in the non-HIPEC arm (26.7 vs. 13.4 months; p \ 0.006) and a percentage of patients surviving 3 years more than four times higher than in the non-HIPEC arm (75% vs. 18%; p \ 0.01). However, the authors do not explain how they performed the statistical analysis, only that it was conducted using SPSS software. At first view, the Kaplan-Meier plot did not seem to support such big differences, therefore we decided to perform a new analysis (using SPSS 15.0.1; SPSS Inc., Chicago, IL, USA) comparing survival of both arms to define the hazard ratio (HR) for overall survival (log rank) for patients treated with HIPEC. We performed a manual extraction of data from the Kaplan-Meier plot published in the original paper, and were able to extract data from 63 patients (53%). As survival in both arms showed a cumulative survival above 60%, we assumed that the other 57 patients remain alive at last follow-up and that their survival data were censored. With our estimated data, we were able to reproduce the original curve presented by the authors in their article. We conducted two exploratory analyses. The first, assuming that these 57 patients were censored immediately after the last death (at 22 months in the non-HIPEC arm and 34 months in the HIPEC arm), shows an HR of 0.58 [95% confidence interval (CI) 0.28-1.17; p = 0.13). In the second analysis, we assumed that these 57 patients were censored along with the patient with longer follow-up (at 32 months in the non-HIPEC arm and 80 months in the HIPEC arm), with an HR of 0.66 (95% CI 0.33-1.30; p = 0.23).
According to these estimations, no significant differences in overall survival could be seen between both arms of the study. We question how the survival analysis was performed, why the authors analyzed mean survival (that use to be biased by patients with longer follow-up, as in this case), and how they entered the data of the censored patients. In addition, we do not understand where the data on the percentage of patients alive at 3 years came from as these results do not fit with the data of the Kaplan-Meier plot that the authors show in their article.
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